Trial · NCT02485301
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects With Solicited Local Adverse Events | During the 7-Day (Days 0-6) post-vaccination period | The analysis was performed on the Total Vaccinated Cohort - Adverse Event (AE) and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Subjects With Solicited General Adverse Events | During the 7-Day (Days 0-6) post-vaccination period | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Subjects With Unsolicited Adverse Events (AEs) | During the 30-Day (Days 0-29) post-vaccination period | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Screening | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Screening. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Day 3 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 3. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Day 6 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 6. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Day 30 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 30. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Month 6 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Month 6 + 6 Days | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6 + 6 Days timepoint. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Month 6 + 30 Days | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6 + 30 Days timepoint. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Haematological Laboratory Abnormalities | At Month 12 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 12. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Screening | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Screening. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Day 3 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 3. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Day 6 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 6. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Day 30 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Day 30. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Month 6 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Month 6 + 6 Days | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6 + 6 Days timepoint. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Month 6 + 30 Days | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 6 + 30 Days timepoint. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Subjects With Biochemical Laboratory Abnormalities | At Month 12 | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented and with available results at Month 12. | Percentage of participants | NUMBER |
| PRIMARY | Number of Subjects With Adverse Events of Specific Interest (AESI) | During the 7-Day (Days 0-6) post-vaccination period | The analysis was performed on the Total Vaccinated Cohort - AE and Humoral Immunity Sub-cohort, which included all subjects with at least one vaccine administration documented. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02485301/outcomes